<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601181</url>
  </required_header>
  <id_info>
    <org_study_id>ThisCART22</org_study_id>
    <nct_id>NCT04601181</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies</brief_title>
  <official_title>A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22 in Patients With Refractory or Relapsed B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundamenta Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundamenta Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical&#xD;
      activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed&#xD;
      CD22-positive B cell malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will receive infusion of ThisCART22 cells from health donor ,to evaluate the&#xD;
      safety and efficacy of ThisCART22 Cells in patients with refractory or relapsed CD22-positive&#xD;
      B cell malignancies.&#xD;
&#xD;
      In this study, the dose range is 0.2-60 x10^6 cells per kg body weight (no more than 3.0 x&#xD;
      10^9 in total).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of AE or SAE of CART cell infusion in relation to the study drug at grade ≥3 (refer to CTCAE version 4.03);</measure>
    <time_frame>From infusion to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR (sum of CR and CRi) after infusion.</measure>
    <time_frame>From infusion to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The survival time of CAR-T-22 cells in vivo;</measure>
    <time_frame>From infusion to month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR at week 4, 8, and 24 after infusion (ORR4, ORR8, ORR24).</measure>
    <time_frame>At week 4, 8, and 24 after infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>B Cell Malignancy</condition>
  <arm_group>
    <arm_group_label>ThisCART22 cells injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ThisCART22 cells injection</intervention_name>
    <description>Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10^6 CAR-T cells per kg body weight.&#xD;
Intervention study</description>
    <arm_group_label>ThisCART22 cells injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who volunteered to participate in the research and signed a written informed&#xD;
             consent;&#xD;
&#xD;
          2. The informed consent was signed between the ages of 3-70, regardless of gender or&#xD;
             race;&#xD;
&#xD;
          3. CD22 positive hematologic malignancies with no alternative treatment options deemed by&#xD;
             investigator. including those who are not eligible for allogeneic stem cell&#xD;
             transplantation (SCT) due to the following reasons： 3.1 age； 3.2 Concurrent disease；&#xD;
             3.3 Other contraindications, such as contraindications to total body irradiation (TBI)&#xD;
             (TBI is one of the important treatment measures before allogeneic stem cell&#xD;
             transplantation of ALL)； 3.4 Lack of suitable donors； 3.5 Patients with relapse after&#xD;
             CD19-CAR T treatment；&#xD;
&#xD;
          4. Estimated life expectancy &gt; 12 weeks deemed by investigator&#xD;
&#xD;
          5. Recurrence after any stem cell transplantation (regardless of previous treatment&#xD;
             regimen);&#xD;
&#xD;
          6. Patients who relapse after previous allogeneic SCT (myeloablative or&#xD;
             non-myeloablative) and meet all the following entry criteria:&#xD;
&#xD;
             6.1 No active GVHD and no immunosuppression is required； 6.2 Transplant for more than&#xD;
             4 months；&#xD;
&#xD;
          7. Serum creatinine ≤1.6 mg/dl and/or BUN ≤ 1.5 mg/dl；&#xD;
&#xD;
          8. Serum ALT/ AST &lt; 5 upper limit of normal (ULN)；&#xD;
&#xD;
          9. Measurable or detectable disease at time of enrollment，include minimal residual&#xD;
             disease (MRD) detected by immunotyping, cytogenetics or PCR.&#xD;
&#xD;
         10. Cardiac ejection fraction ≥ 40%.&#xD;
&#xD;
         11. Eastern cooperative oncology group (ECOG) performance status of ≤ 2.&#xD;
&#xD;
         12. Female subjects with fertility have a negative pregnancy test result within 48 hours&#xD;
             before the infusion and are not breast-feeding; all subjects with fertility potential&#xD;
             before being enrolled in the study and throughout the study period until the last&#xD;
             infusion Within 3 months, take adequate contraceptive measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Participated in another clinical trial during the first 4 weeks of the enrolled study&#xD;
             or intended to participate in another clinical trial throughout the study period;&#xD;
&#xD;
          3. Have been treated with any gene product;&#xD;
&#xD;
          4. Uncontrolled infection;&#xD;
&#xD;
          5. History of HIV infection;&#xD;
&#xD;
          6. Active hepatitis B virus or hepatitis C virus infection;&#xD;
&#xD;
          7. Systemic steroid therapy may be required for cell infusion or collection, or there may&#xD;
             be conditions that the investigator considers may require steroid therapy during blood&#xD;
             collection or infusion.Corticosteroids for disease treatment are permitted, and&#xD;
             inhaled steroids or hydrocortisone physiologic replacement therapy for patients with&#xD;
             adrenocortical dysfunction is permitted beyond the time of cell collection or&#xD;
             infusion;&#xD;
&#xD;
          8. Patients with grade 2-4 GVHD, or deemed need to manage by investigator;&#xD;
&#xD;
          9. The presence of GVHD under treatment;.&#xD;
&#xD;
         10. Patients with active CNS involvement by malignancy;&#xD;
&#xD;
         11. Patients combine with other disease cause neutrophil count (ANC) &lt;750/uL or PLT&lt;&#xD;
             50,000/uL&#xD;
&#xD;
         12. The researchers considered the subjects unsuitable for this clinical trial for various&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingbing Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingbing Wang, M.D.</last_name>
    <phone>+8613856007984</phone>
    <email>wangxingbing@ustc.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling He</last_name>
    <phone>+8618626100886</phone>
    <email>lhe@ctigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingbing Wang, M.D.</last_name>
      <phone>+8613856007984</phone>
      <email>wangxingbing@ustc.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jun Li, Ph.D.</last_name>
      <phone>+8618662604088</phone>
      <email>jli@ctigen.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xingbing Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

